SC
PHVS icon

Stempoint Capital’s Pharvaris PHVS Stock Holding History

Stempoint Capital’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.45M Buy
86,637
+28,248
+48% +$754K 0.47% 49
2025
Q4 		$1.62M Buy
+58,389
New +$1.41M 0.28% 61

Other funds holding PHVS

GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $1.02B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Stempoint Capital's PHVS Position: Q1 2026 in Review

Stempoint Capital increased its Pharvaris (PHVS) stake by 48% in Q1 2026, buying an estimated $754K and bringing the position to 86,637 shares worth $2.45M. The position accounts for 0.47% of the portfolio, ranked #49.

Stempoint Capital first reported a position in PHVS in Q4 2025 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

  • Stempoint Capital held 86,637 shares of Pharvaris worth $2.45M as of Q1 2026.
  • Stempoint Capital bought 28,248 Pharvaris shares in Q1 2026, an estimated $754K.
  • Pharvaris made up 0.47% of Stempoint Capital's portfolio in Q1 2026, its #49 holding.
  • Stempoint Capital first reported a position in Pharvaris in Q4 2025 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.